Key highlights Semaglutide is a popular and effective GLP-1 receptor agonist used for diabetes management and weight loss in overweight or obese individuals
Adverse events such as diarrhea, constipation, nausea, and vomiting associated with the GLP-1 RAs overlap with those seen with cancer treatments, so the patient who is undergoing treatment with an emetogenic regimen for cancer will likely experience additional weight loss, which can lead to nutritional deficiencies, loss of lean muscle mass, and loss of bone mass
10.1016/S0735-1097(87)80124-9 40
Who Saxenda Is Best For Saxenda may be especially useful for individuals who: Prefer a daily dose rather than a weekly injection Need a gentler appetite-regulating tool Have gastrointestinal side effects on higher potency weekly agents Have insurance plans that cover liraglutide but not semaglutide or tirzepatide Want a gradual, steady shift in appetite patterns rather than a rapid one Are early in their weight loss journey and want to build confidence before transitioning to other therapies Saxenda is also an option for patients preparing for bariatric surgery who require moderate appetite control, blood sugar stabilization, or weight reduction prior to the operation
Nora Volkow, director of the National Institute on Drug Abuse at the National Institutes of Health, who has done similar work analyzing medical records to assess GLP-1 drugs
9.^ (accessed May 17, 2022)
